Eli Lilly (LLY) Secures High Court Approval for $7.8 Billion Centessa (CNTA) Acquisition

Eli Lilly (LLY) has secured High Court approval for its $7.8 billion acquisition of Centessa Pharmaceuticals (CNTA), moving the significant pharmaceutical deal closer to completion. This regulatory milestone advances Eli Lilly's strategic expansion in the biotech sector. The approval, granted on June 23, 2026, enables Eli Lilly to proceed with integrating Centessa's assets. The acquisition is poised to enhance Eli Lilly's therapeutic pipeline and bolster its market position within the pharmaceutical industry.